RICHMAN ERIC I

Average Profitability
26.06%
Insider Buys Quantity
9
Insider Buys Sum
$287,457.39
Insider Sells Quantity
3
Insider Sells Sum
$225,896.00

Insider Activity of RICHMAN ERIC I

According to the SEC Form 4 filings, RICHMAN ERIC I, being in a position of

  1. director at Gain Therapeutics, Inc.,
    оver the last 12 months, has bought 17000 shares for $20,670, and sold 0 shares,
    over all time since 2021-08-16, has bought 33660 shares for $91,984, and sold 0 shares.

The largest purchase of all time was on 2015-03-13 and amounted to 7000 shares of ADMA Biologics, Inc. for $55,140.

The largest sale of all time was on 2016-04-13 and amounted to 88233 shares of Altimmune, Inc. for $188,290.

Biography of RICHMAN ERIC I

No biography is available at this moment.

2024-07-01PurchaseGain Therapeutics, Inc.
GANX
director
17,000
0.0902%
$1.22$20,6700%
2022-05-25PurchaseGain Therapeutics, Inc.
GANX
CHIEF EXECUTIVE OFFICER
2,482
0.0203%
$2.58$6,404+43.21%
2022-05-19PurchaseGain Therapeutics, Inc.
GANX
CHIEF EXECUTIVE OFFICER
9,256
0.0816%
$2.83$26,194+39.63%
2021-08-16PurchaseGain Therapeutics, Inc.
GANX
Chief Executive Officer
4,922
0.042%
$7.87$38,716-45.68%
2018-06-08PurchaseADMA Biologics, Inc.
ADMA
director
5,230
0.0123%
$4.78$24,999+1.05%
2017-11-09PurchaseADMA Biologics, Inc.
ADMA
director
25,000
0.0494%
$2.15$53,750+103.33%
2016-04-13SaleAltimmune, Inc.
ALT
director
88,233
5.0849%
$2.13$188,290+26.13%
2016-04-08SaleAltimmune, Inc.
ALT
director
12,800
0.7889%
$2.20$28,160+30.84%
2016-04-07SaleAltimmune, Inc.
ALT
director
5,367
0.2574%
$1.76$9,446+27.27%
2015-03-13PurchaseADMA Biologics, Inc.
ADMA
director
7,000
0.0722%
$7.88$55,140+14.84%
2011-11-10PurchaseAltimmune, Inc.
ALT
President and CEO
20,000
0.0013%
$1.50$30,050+0.22%
2010-06-17PurchaseAltimmune, Inc.
ALT
President and Interim CEO
20,000
0.0021%
$1.58$31,534+1.05%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.